Emjard™ is a prescription medication manufactured by Square Pharmaceuticals Ltd. in Bangladesh. It contains Empagliflozin 25 mg, a Sodium-glucose co-transporter 2 (SGLT2) inhibitor used to manage type 2 diabetes mellitus and reduce the risk of cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.